Patents by Inventor Olivier Dubreuil

Olivier Dubreuil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11001634
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: May 11, 2021
    Assignees: GAMAMABS PHARMA, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Thierry Chardès, Olivier Dubreuil, André Pelegrin, Christel Larbouret, Jean-François Prost, Jean-Marc Barret, Stéphane Degove
  • Patent number: 10509035
    Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: December 17, 2019
    Assignee: GAMAMABS PHARMA SA
    Inventors: Olivier Dubreuil, Jean-Marc Barret, Jean-François Prost, Delphine Desigaud
  • Publication number: 20190367625
    Abstract: The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a cancer selected in a group of cancers comprising colon cancer, liver cancer, hepatocellular carcinoma, testis cancer, thyroid cancer, gastric cancer, gastrointestinal cancer, bladder cancer, pancreatic cancer, head and neck cancer, kidney cancer, liposarcoma, pleuramesothelioma, melanoma, sarcoma, brain cancer, osteocarcinoma and leukemia.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 5, 2019
    Inventors: Jean-Marc BARRET, Jean-François PROST, Mehdi LAHMAR, Stéphane DEGOVE, Olivier DUBREUIL, André NICOLAS, Didier MESURE
  • Publication number: 20180155433
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Application
    Filed: May 2, 2016
    Publication date: June 7, 2018
    Inventors: Thierry CHARDÈS, Olivier DUBREUIL, André PELEGRIN, Christel LARBOURET, Jean-François PROST, Jean-Marc BARRET, Stéphane DEGOVE
  • Publication number: 20170035903
    Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 9, 2017
    Inventors: OLIVIER DUBREUIL, JEAN-MARC BARRET, JEAN-FRANÇOIS PROST, DELPHINE DESIGAUD
  • Patent number: 9346883
    Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: May 24, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Gamamabs Pharma SA
    Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
  • Publication number: 20140141019
    Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 22, 2014
    Applicant: INSERM (INSTITUT NATIONALDE LA SENTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
  • Patent number: 8257506
    Abstract: The present invention relates to a cost saving liquid-treatment unit (100). According to the invention, a control unit (152), which is connected to an input port of a control valve (118, 120, 122), is adapted to set, in dependence on the evaporation rate of a treatment liquid on the substrate at the given or desired temperature of the substrate and/or at the given or desired pressure of a gaseous ambient atmosphere at the substrate, a number of dispense pulses to be applied to the substrate for the liquid treatment, a respective pulse duration of individual dispense pulses, and respective dispense-interruption time spans between the individual dispense pulses. This way, the use of treatment liquid is reduced to a minimum amount, thus reducing costs for providing and cleaning treatment liquid.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: September 4, 2012
    Assignee: NXP B.V.
    Inventors: Olivier Dubreuil, Srdjan Kordic, Theodore Carambeeris
  • Publication number: 20090007938
    Abstract: The present invention relates to a cost saving liquid-treatment unit (100). According to the invention, a control unit (152), which is connected to an input port of a control valve (118, 120, 122), is adapted to set, in dependence on the evaporation rate of a treatment liquid on the substrate at the given or desired temperature of the substrate and/or at the given or desired pressure of a gaseous ambient atmosphere at the substrate, a number of dispense pulses to be applied to the substrate for the liquid treatment, a respective pulse duration of individual dispense pulses, and respective dispense-interruption time spans between the individual dispense pulses. This way, the use of treatment liquid is reduced to a minimum amount, thus reducing costs for providing and cleaning treatment liquid.
    Type: Application
    Filed: February 1, 2007
    Publication date: January 8, 2009
    Applicant: NXP B.V.
    Inventors: Olivier Dubreuil, Srdjan Kordic, Theodore Caramberis